On June 23, Argenx SE rose 3.08% in regular trading, trading at $931.58/share, with turnover of $134 million.

On the news front, BNP Paribas recently rated Argenx as Outperform and issued a target price of $1,219, implying approximately 31% upside from current levels. According to FactSet data, the stock carries an average analyst rating of Buy with a consensus target price of $1,064.53. BNP Paribas's target sits meaningfully above market consensus, providing a positive boost to market sentiment.

Argenx SE is a commercial-stage global biopharmaceutical company focused on developing differentiated therapies for severe autoimmune diseases. Its lead product efgartigimod generated $1.3 billion in revenue in Q1, representing 62.5% year-over-year growth. The company reported net income of $366 million, with R&D expenses of $400 million reflecting continued pipeline investment. The next earnings report is scheduled for July 23 pre-market.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)